1
|
Liu Y, Wang CW, Chen CB, Yu KH, Wu YJ, Choon SE, Chang WC, Yang F, Luo XQ, Chung WH, Zhao M, Lu QJ. DNA methylation of ITGB2 contributes to allopurinol hypersensitivity. Clin Immunol 2023; 248:109250. [PMID: 36738816 DOI: 10.1016/j.clim.2023.109250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 01/28/2023] [Accepted: 01/30/2023] [Indexed: 02/05/2023]
Abstract
BACKGROUNDS HLA-B*58:01 allele was strongly associated with allopurinol induced severe cutaneous adverse drug reaction (SCAR). However, HLA-B genotype is not sufficient to predict the occurrence of allopurinol-induced SCAR. OBJECTIVE To discover DNA methylation markers for allopurinol-induced SCAR which may improve the prediction accuracy of genetic testing. STUDY DESIGN The study was designed as a retrospective case-control clinical study in multicenter hospitals across Taiwan, Mainland China, Malaysia and Canada. 125 cases of allopurinol-induced SCAR patients and 139 cases of allopurinol tolerant controls were enrolled in this study during 2005 to 2021. RESULTS The results of genome-wide DNA methylation assay of 62 patients revealed that ITGB2 showed strong discriminative ability of allopurinol-induced SCAR in both HLA-B*58:01 positive and negative patients with AUC value of 0.9364 (95% CI 0.8682-1.000). In validation study, significant hypermethylation of ITGB2 were further validated in allopurinol-induced SCAR patients compared to tolerant controls, especially in those without HLA-B*58:01(AUC value of 0.8814 (95% CI 0.7121-1.000)). Additionally, the methylation levels of 2 sites on ITGB2 were associated with SCAR phenotypes. Combination of HLA-B*58:01 genotyping and ITGB2 methylation status could improve the prediction accuracy of allopurinol-induced SCAR with the AUC value up to 0.9387 (95% CI 0.9089-0.9684), while the AUC value of HLA-B*58:01 genotyping alone was 0.8557 (95% CI 0.8030-0.9083). CONCLUSIONS Our study uncovers differentially methylated genes between allopurinol-induced SCAR patients and tolerant controls with positive or negative HLA-B*58:01 allele and provides the novel epigenetic marker that improves the prediction accuracy of genetic testing for prevention of allopurinol-induced SCAR.
Collapse
Affiliation(s)
- Yu Liu
- Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Chuang-Wei Wang
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan China; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan China; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, China; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
| | - Chun-Bing Chen
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan China; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan China; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, China; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China; Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan China; College of Medicine, Chang Gung University, Taoyuan, Taiwan China
| | - Kuang-Hui Yu
- College of Medicine, Chang Gung University, Taoyuan, Taiwan China; Division of Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan China
| | - Yeong-Jian Wu
- College of Medicine, Chang Gung University, Taoyuan, Taiwan China; Division of Allergy, Immunology and Rheumatology, Department of Medicine, Chang Gung Memorial Hospital, Keelung and Linkou, Taiwan China
| | - Siew-Eng Choon
- Hospital Sultanah Aminah, Clinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Malaysia
| | - Wan-Chun Chang
- Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada
| | - Fanping Yang
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
| | - Xiao-Qun Luo
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
| | - Wen-Hung Chung
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan China; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan China; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, China; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China; Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan China; College of Medicine, Chang Gung University, Taoyuan, Taiwan China; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan China; Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China; School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan China.
| | - Ming Zhao
- Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China; Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China; Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China; Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, China.
| | - Qian-Jin Lu
- Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China; Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China; Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China; Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, China.
| |
Collapse
|
2
|
Zhang W, Chen N, Wang W, He J, Zhu F. Identification of the novel HLA-DRB1*04:316 allele by next-generation sequencing in a Chinese bone marrow donor. HLA 2023; 101:75-77. [PMID: 36114732 DOI: 10.1111/tan.14822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Accepted: 09/14/2022] [Indexed: 12/13/2022]
Abstract
HLA-DRB1*04:316 differs from HLA-DRB1*04:03:01:01 by one nucleotide substitution at position 161 in exon 2.
Collapse
Affiliation(s)
- Wei Zhang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,HLA typing laboratory, Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - Nanying Chen
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,HLA typing laboratory, Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - Wei Wang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,HLA typing laboratory, Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - Ji He
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,HLA typing laboratory, Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - Faming Zhu
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,HLA typing laboratory, Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| |
Collapse
|
3
|
Wang F, Dong L, Wang W, Chen N, Zhang W, He J, Zhu F. The polymorphism of HLA-A, -C, -B, -DRB3/4/5, -DRB1, -DQB1 loci in Zhejiang Han population, China using NGS technology. Int J Immunogenet 2021; 48:485-489. [PMID: 34553840 DOI: 10.1111/iji.12554] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 08/09/2021] [Accepted: 08/11/2021] [Indexed: 11/26/2022]
Abstract
The distributions of HLA allele and haplotype are various in the populations. Currently, the data for HLA alleles and haplotypes at three fields resolution level in Chinese Han population is rare. Here, the HLA alleles and haplotypes of the 1734 cord blood samples from Zhejiang Han population, China were reported at three fields resolution. All samples were randomly collected from the Zhejiang Cord Blood Bank, China. HLA-A, -B, -C, -DRB1, -DQB1, -DRB3/4/5 loci was genotyped using next generation sequencing method. The genotypes of the samples were assigned using the HLA TypeStream Visual Software version 1.2.0. The frequency of alleles, haplotype estimation and linkage disequilibrium analysis were performed with the Arlequin software 3.5.2.2. It was found that the top three frequent alleles of HLA-A, -B, -C, -DRB1, -DQB1, -DRB3/4/5 loci were A*11:01:01 (25.81%), A*24:02:01 (16.70%), A*02:01:01 (10.61%); B*40:01:02 (15.97%), B*46:01:01 (11.48%), B*58:01:01 (7.96%); C*07:02:01 (19.03%), C*01:02:01 (17.65%), C*03:04:01 (10.41%); DRB1*09:01:02G (17.96%), DRB1*12:02:01 (9.57%), DRB1*08:03:02 (9.54%); DQB1*03:01:01G (21.05%), DQB1*03:03:02 (19.15%), DQB1*06:01:01G (12.08%); DRB4*01:03:01 (25.72%), DRB3*02:02:01 (20.27%), DRB5*01:01:01 (10.96%), respectively. A total of 1528 distinct A∼C∼B∼DRB3/4/5∼DRB1∼DQB1 haplotypes were estimated, and the top three most common haplotypes were A*33:03:01∼C*03:02:02∼B*58:01:01∼DRB3*02:02:01∼DRB1*03:01:01∼ DQB1*02:01:01 (4.02%), A*30:01:01∼C*06:02:01∼B*13:02:01∼DRB4*01:03:01∼ DRB1*07:01:01 ∼DQB1*02:02:01 (3.11%) and A*02:07:01∼C*01:02:01∼B*46:01:01 ∼DRB4*01:03:01∼DRB1*09:01:02G∼DQB1*03:03:02 (3.05%). Some alleles of different HLA loci were shown strong linkage disequilibrium. In conclusion, the data of allele and haplotype of HLA-A, -B, -C, -DRB1, -DQB1 and -DRB3/4/5 loci at three fields resolution level were obtained in Zhejiang Han population, thus contributing to analyze the HLA ploymorphism in the populations.
Collapse
Affiliation(s)
- Fang Wang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang Province, China.,Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang Province, 310052, China
| | - Lina Dong
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang Province, China.,Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang Province, 310052, China
| | - Wei Wang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang Province, China.,Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang Province, 310052, China
| | - Nanying Chen
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang Province, China.,Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang Province, 310052, China
| | - Wei Zhang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang Province, China.,Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang Province, 310052, China
| | - Ji He
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang Province, China.,Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang Province, 310052, China
| | - Faming Zhu
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang Province, China.,Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang Province, 310052, China
| |
Collapse
|
4
|
Song T, Zhang Y, Huang J, Liu Z. Transfusion-induced platelet antibodies and regulatory T cells in multiply transfused patients. J Clin Lab Anal 2021; 35:e23864. [PMID: 34125970 PMCID: PMC8275002 DOI: 10.1002/jcla.23864] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 04/29/2021] [Accepted: 05/18/2021] [Indexed: 12/03/2022] Open
Abstract
Background Platelet transfusion refractoriness (PTR) remains a difficult problem in patients requiring long‐term platelet supportive care. However, there are little data on the frequency of platelet antibodies in multiply transfused Chinese patients. Moreover, the relationship between peripheral regulatory T cells (Tregs) and PTR remains unclear. Methods We retrospectively studied the frequency of alloimmunization against platelet antigens in patients receiving multiple transfusions between 2013 and 2017. Monoclonal antibody solid‐phase platelet antibody test (MASPAT) kits were used to screen for platelet antibodies before each platelet transfusion. Peripheral Tregs and CD4+CD25+CD127− T cells were detected by flow cytometry, while transforming growth factor‐beta (TGF‐β) and interleukin (IL)‐17 cytokines were detected by enzyme‐linked immunosorbent assay. Results A total of 399 patients who met the inclusion criteria were enrolled for the analysis of platelet antibodies and refractoriness. Among these patients, 10 (2.5%) were positive for platelet antibodies before transfusion and 47 (11.8%) became antibody‐positive during the study period. The number of alloimmunized patients was significantly higher in patients with hematological disease as compared with other disease groups (p < 0.05). Refractoriness and alloimmunization occurred in 77 (19.3%) and 22 (28.6%) patients, respectively. There were no significant differences in CD4+, CD8+, and CD4+CD25+CD127− T cell numbers and plasma levels of TGF‐β1 and IL‐17 between patients with PTR and the control group. Conclusions Refractoriness was common in patients undergoing multiple platelet transfusions (19.3%), with alloimmunization observed in 28.6% of patients. However, Tregs in peripheral blood may not play a key role in PTR.
Collapse
Affiliation(s)
- Tiejun Song
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Ying Zhang
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Jun Huang
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Zhiwei Liu
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| |
Collapse
|
5
|
Baek IC, Choi EJ, Shin DH, Kim HJ, Choi H, Kim TG. Distributions of HLA-A, -B, and -DRB1 alleles typed by amplicon-based next generation sequencing in Korean volunteer donors for unrelated hematopoietic stem cell transplantation. HLA 2021; 97:112-126. [PMID: 33179442 DOI: 10.1111/tan.14134] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 09/23/2020] [Accepted: 11/04/2020] [Indexed: 01/20/2023]
Abstract
HLA genes play a pivotal role for successful hematopoietic stem cell transplantation (HSCT). There is an increasing need for sophisticated screening of donor HLA genotypes for unrelated HSCT. Next generation sequencing (NGS) has emerged as an alternative for classical Sanger sequence for HLA typing. In this study, HLA-A, -B, and -DRB1 alleles were genotyped at the allelic (6-digit) level using MiSeqDx in 26,202 volunteers from the Korean Network for Organ Sharing. Exon 2 and 3 of HLA-A and -B and exon 2 of HLA-DRB1 were amplified by polymerase chain reaction (PCR) and each allele was determined by matching the targeted exons and the reference sequence consisting of the IPD-IMGT/HLA Database. Seventy alleles of HLA-A, 102 alleles of HLA-B, and 69 alleles of HLA-DRB1 were identified. According to common and well-documented catalogs, 34 alleles in HLA-A, 61 in HLA-B, and 45 in HLA-DRB1 locus were common alleles, and 12, 14, and 11 kinds, were well-documented alleles, respectively. Thirteen novel alleles including 3 alleles in HLA-A, 8 alleles in HLA-B, and 2 alleles in HLA-DRB1 loci were found. Ten haplotypes with a frequency of more than 1.0% accounted for 22.4% of the total haplotype frequencies. Cis/trans ambiguities of HLA-A and -B loci by combination of exons 2 and 3 were analyzed to be 0.17% of 3 and 3.95% of 22 genotypes, respectively. This information on rare and novel alleles found by accurate HLA typing with NGS may be helpful for unrelated HSCT among Koreans.
Collapse
Affiliation(s)
- In-Cheol Baek
- Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Eun-Jeong Choi
- Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Dong-Hwan Shin
- Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Hyoung-Jae Kim
- Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Haeyoun Choi
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Tai-Gyu Kim
- Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, South Korea.,Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| |
Collapse
|
6
|
Min GJ, Kim HJ, Kim TG, Hyun YS, Hyun SJ, Baek IC, Yoon SY, Park SS, Park S, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW. Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia. HLA 2020; 96:445-455. [PMID: 32506817 DOI: 10.1111/tan.13966] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 05/05/2020] [Accepted: 06/03/2020] [Indexed: 12/11/2022]
Abstract
Some HLA alleles have been shown to be associated with susceptibility to cytomegalovirus (CMV) disease incidence in vitro. The objective of this study was to identify correlations between donor HLA allotypes and CMV disease incidence in patients with acute myeloid leukemia who had undergone allogeneic hematopoietic stem cell transplantation (HSCT). Methods and materials we retrospectively analyzed the medical records of 613 donors and recipients with acute myeloid leukemia who had received an allogeneic HSCT from matched sibling (n = 260), unrelated (n = 168), or haploidentical (n = 186) donors, from 2012 to 2017. The HLA-A, -B, -C, and -DRB1 allotypes in the donors were determined using sequence-based typing. Overall, CMV disease incidence was significantly associated with three genotype alleles, HLA-A*30:04:01G, -B*51:01:01G, and -DRB1*09:01:02G. In the donor CMV IgG seropositive subgroup, CMV disease incidence was significantly associated with HLA-B*51:01:01G and -DRB1*09:01:02G. In the IgG seropositive donors in the unrelated allo-HSCT subgroup CMV disease incidence was also significantly associated with HLA-B*51:01:01G. In the CMV seropositive donors in the haploidentical allo-HSCT subgroup, the incidence of CMV disease was significantly associated with HLA-A*24:02:01G and -DRB1*09:01:02G. HLA-DRB1*13:02:01G was a protective marker among IgG seropositive donors in the unrelated allo-HSCT recipient category. Discussion and conclusions The incidence of CMV disease among HSCT recipients varies according to donor HLA alleles and the donor CMV IgG serostatus. Certain donor HLA alleles can be considered to be risk or protective markers. Donors' HLA types and CMV IgG serostatus should be considered in donor selection.
Collapse
Affiliation(s)
- Gi-June Min
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Hee-Je Kim
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Tai-Gyu Kim
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - You-Seok Hyun
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Seung-Joo Hyun
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - In-Cheol Baek
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Seug Yun Yoon
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Sung-Soo Park
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Silvia Park
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Jae-Ho Yoon
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Sung-Eun Lee
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Byung-Sik Cho
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Ki-Seong Eom
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Yoo-Jin Kim
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Seok Lee
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Chang-Ki Min
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Seok-Goo Cho
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Dong-Wook Kim
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Jong Wook Lee
- Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| |
Collapse
|
7
|
Wang F, Wang W, Zhang W, He J, Faming Z. Characterization of the novel HLA-B*46:01:23 allele in a Chinese bone marrow donor. HLA 2019; 93:224-226. [PMID: 30663280 DOI: 10.1111/tan.13470] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 01/16/2019] [Indexed: 11/29/2022]
Abstract
HLA-B*46:01:23 shows a substitution G to A at position 873 when compared to HLA-B*46:01:01.
Collapse
Affiliation(s)
- Fang Wang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Blood Center of Zhejiang Province, Hangzhou, China
| | - Wei Wang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Blood Center of Zhejiang Province, Hangzhou, China
| | - Wei Zhang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Blood Center of Zhejiang Province, Hangzhou, China
| | - Ji He
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Blood Center of Zhejiang Province, Hangzhou, China
| | - Zhu Faming
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China
| |
Collapse
|
8
|
Chen N, Wang W, Wang F, Dong L, Zhao S, Zhang W, He J, Huang H, Zhu F. The distributions of HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 allele and haplotype at high-resolution level in Zhejiang Han population of China. Int J Immunogenet 2018; 46:7-16. [DOI: 10.1111/iji.12411] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 10/16/2018] [Accepted: 11/25/2018] [Indexed: 01/03/2023]
Affiliation(s)
- Nanying Chen
- Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine; Zhejiang University; Hangzhou China
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| | - Wei Wang
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| | - Fang Wang
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| | - Lina Dong
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| | - Shuoxian Zhao
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| | - Wei Zhang
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| | - Ji He
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| | - He Huang
- Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine; Zhejiang University; Hangzhou China
| | - Faming Zhu
- Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research of Zhejiang Province; Hangzhou China
| |
Collapse
|
9
|
Xu J, Shi X, Qiu Y, Zhang Y, Chen S, Shi Y, Deng Y. Association between HLA-A*3201 allele and oxcarbazepine-induced cutaneous adverse reactions in Eastern Han Chinese population. Seizure 2019; 65:25-30. [PMID: 30599396 DOI: 10.1016/j.seizure.2018.12.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 12/02/2018] [Accepted: 12/17/2018] [Indexed: 01/19/2023] Open
Abstract
PURPOSE To determine genetic associations between oxcarbazepine (OXC)-induced cutaneous adverse drug reactions (cADRs) and human leukocyte antigen (HLA) variants in the Eastern Han Chinese population. METHODS A total of 120 patients were enrolled in this study, including 30 subjects with OXC-induced cADRs (case group) and 90 OXC-tolerant patients (control group). High-resolution HLA genotyping was conducted for HLA-A, HLA-B, HLA-C, and HLA-DRB1, and allele frequencies were compared. RESULTS No patient carried the HLA-B *1502 allele in the case group, the frequency of HLA-B *1502 allele in the control group was 6.1%. HLA-A*3201 allele was detected in 13.3% of 30 patients with OXC-induced cADRs (4/30) and 0% of 90 OXC-tolerant patients (0/90). The difference in HLA-A*3201 frequency between the two groups was statistically significant [P = 0.004, odds ratio (OR) = 15.877, 95% confidence interval (CI) = 1.817-138.720]. CONCLUSIONS Eastern Han Chinese patients with the HLA-A*3201 allele may be more susceptible to OXC-induced cADRs, while the HLA-B*1502 allele is not correlated with it. The precise association between HLA alleles and OXC-induced cADRs warrants further study.
Collapse
|
10
|
Abstract
Introduction: Pharmacogenetic testing may assist in identifying an individual's risk of developing a mental illness as well as predict an individual's response to treatment. The objective of this study is to report published outcomes of pharmacogenetic testing in patients with schizophrenia or bipolar disorder. Methods: A systematic review using PubMed and EBSCOhost through April 2017 was performed to identify articles that reported pharmacogenetic testing in adult patients with either bipolar disorder or schizophrenia using the keywords pharmacy, pharmacogenomics, pharmacogenetics, psychiatry, bipolar disorder, schizophrenia, mood stabilizer, and antipsychotic. Results: A total of 18 articles were included in the final literature review. A wide variety of genes amongst adult patients with varying ethnicities were found to be correlated with the development of schizophrenia or bipolar disorder as well as response to antipsychotics and mood stabilizers. Discussion: While current studies show a correlation between genetic variations and medication response or disease predisposition for patients with schizophrenia and bipolar disorder, research is unclear on the type of therapeutic recommendations that should occur based on the results of the pharmacogenetic testing. Hopefully interpreting pharmacogenetic results will one day assist with optimizing medication recommendations for individuals with schizophrenia and bipolar disorder.
Collapse
Affiliation(s)
- Melanie Routhieaux
- PGY-1 Pharmacy Practice Resident, William Jennings Bryan Dorn VA Medical Center, Columbia, South Carolina
| | - Jessica Keels
- PGY-1 Pharmacy Practice Resident, William Jennings Bryan Dorn VA Medical Center, Columbia, South Carolina
| | - Erika E Tillery
- (Corresponding author) Associate Professor of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, South Carolina; Clinical Psychiatric Pharmacist, Division of Inpatient Services, G. Werber Bryan Psychiatric Hospital, Columbia, South Carolina,
| |
Collapse
|
11
|
Feng X, Li W, Song J, Liu X, Gu Y, Yan C, Wu H, Xi J, Zhou S, Zhao C. HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients. J Clin Neurosci 2018; 59:179-184. [PMID: 30595166 DOI: 10.1016/j.jocn.2018.10.077] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Revised: 09/27/2018] [Accepted: 10/14/2018] [Indexed: 11/15/2022]
Abstract
To compare HLA typing between juvenile- and adult-onset myasthenia gravis (MG), we enrolled 101 children (age ≤12 years) and 168 adults (age ≥20 years) with MG. We excluded patients with histories of thymoma, thyroid disease, or other autoimmune disease. We selected 41 seronegative juvenile-onset patients with ocular symptoms only, and 41 seropositive adult-onset patients with generalized symptoms. We used next-generation sequencing for typing and analysis of HLA genes (Loci: A, B, C, DPA1, DPB1, DQA1, DQB1 and DRB1). Haplotypes HLA-A∗02:07:01-B∗46:01:01-C∗01:02:01-DQA1∗01:01:01-DQB1∗03:03:02-DRB1∗09:01:02, HLA-A∗11:01:01, HLA-A∗24:02:01, and HLA-DPA1∗02:02:02 were found to be related to juvenile-onset MG and HLA-A∗01:01:01, HLA-A∗02:03:01, HLA-C∗03:04:01, and HLA-DQB1∗06:02:01 to adult-onset MG. Therefore, our findings suggested that HLA typing might determine the heterogeneity between AChR-Ab negative juvenile-onset and AChR-Ab positive adult-onset Chinese MG patients.
Collapse
Affiliation(s)
- Xuelin Feng
- Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, China
| | - Wenhui Li
- Department of Neurology, Children's Hospital of Fudan University, Shanghai, China
| | - Jie Song
- Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, China
| | - Xiaoni Liu
- Institute of Neurology, Fudan University, Shanghai, China
| | - Yuehua Gu
- Institute of Neurology, Fudan University, Shanghai, China
| | - Chong Yan
- Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, China
| | - Hui Wu
- Department of Neurology, Jing'an District Centre Hospital of Shanghai, China
| | - Jianying Xi
- Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, China
| | - Shuizhen Zhou
- Department of Neurology, Children's Hospital of Fudan University, Shanghai, China.
| | - Chongbo Zhao
- Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, China; Department of Neurology, Jing'an District Centre Hospital of Shanghai, China.
| |
Collapse
|
12
|
Wang W, Chen N, Dong L, He Y, Tao S, Zhang W, He J, Chen J, Zhu F. Characterization of three new HLA Class I Alleles in Chinese individuals, HLA-B*46:68,-B*46:71,-B*46:72. Int J Immunogenet 2018; 45:351-353. [PMID: 30117674 DOI: 10.1111/iji.12394] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2018] [Revised: 06/13/2018] [Accepted: 06/21/2018] [Indexed: 11/29/2022]
Abstract
Three new HLA class I alleles were described in the Chinese population. HLA-B*46:68,-B*46:71,-B*46:72 alleles differ from HLA-B*46:01:01 by a single nucleotide substitution at position 485C>T, 484A>G, 299T>A respectively.
Collapse
Affiliation(s)
- Wei Wang
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Nanying Chen
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Lina Dong
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Yanmin He
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Sudan Tao
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Wei Zhang
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Ji He
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Jiangtian Chen
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| | - Faming Zhu
- Blood Center of Zhejiang Province, Hangzhou, China.,Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, China
| |
Collapse
|
13
|
Pei Y, Huang H, Li H, Chen J, Wu G. Allelic and haplotype diversity of HLA-A, HLA-B and HLA-DRB1 gene at high resolution in the Nanning Han population. Int J Immunogenet 2018; 45:201-209. [DOI: 10.1111/iji.12379] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 03/26/2018] [Accepted: 04/13/2018] [Indexed: 12/22/2022]
Affiliation(s)
- YongFeng Pei
- Nanning Blood Center; Nanning Institute of Transfusion Medicine; Nanning China
| | - HuiNi Huang
- Nanning Blood Center; Nanning Institute of Transfusion Medicine; Nanning China
| | - HengCong Li
- Nanning Blood Center; Nanning Institute of Transfusion Medicine; Nanning China
| | - JieRun Chen
- Nanning Blood Center; Nanning Institute of Transfusion Medicine; Nanning China
| | - GuoGuang Wu
- Nanning Blood Center; Nanning Institute of Transfusion Medicine; Nanning China
| |
Collapse
|
14
|
Fan PW, Huang L, Chang XM, Feng YN, Yao X, Peng YC, Dong T, Wang RZ. Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood. Chin Med J (Engl) 2018; 131:1289-1295. [PMID: 29786040 PMCID: PMC5987498 DOI: 10.4103/0366-6999.232791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Background: Development of innovative immunotherapy is imperative to improve the poor survival of the nasopharyngeal carcinoma (NPC) patients. In this study, we evaluated the T cell response to melanoma-associated antigen (MAGE)-A1, MAGE-A3, or synovial sarcoma X-2 (SSX-2) in the peripheral blood of treatment-naive NPC patients. The relationship of responses among the three proteins and the human leukocyte antigen (HLA)-A types were analyzed to provide evidence of designing novel therapy. Methods: Sixty-one NPC patients admitted into the Tumor Hospital affiliated to the Xinjiang Medical University between March 2015 and July 2016 were enrolled. Mononuclear cells were isolated from the peripheral blood before any treatment. HLA-A alleles were typed with Sanger sequence-based typing technique. The T cell response to the MAGE-A1, MAGE-A3, or SSX-2 was evaluated with the Enzyme-Linked ImmunoSpot assay. Mann-Whitney U-test was used to compare the T cell responses from different groups. Spearman's rank correlation was used to analyze the relationship of T cell responses. Results: HLA-A*02:01, A*02:07, and A*24:02 were the three most frequent alleles (18.9%, 12.3%, and 11.5%, respectively) among the 22 detected alleles. 31.1%, 19.7%, and 16.4% of the patients displayed MAGE-A1, MAGE-A3, or SSX-2-specific T cell response, respectively. The magnitudes of response to the three proteins were 32.5, 38.0, and 28.7 SFC/106 peripheral blood mononuclear cells, respectively. The T cell response against the three proteins correlated with each other to different extent. The percentage of A*02:01 and A*24:02 carriers were significantly higher in patients responding to any of the three proteins compared to the nonresponders. Conclusion: MAGE-A1, MAGE-A3, or SSX-2-specific T cell responses were detectable in a subgroup of NPC patients, the frequency and magnitude of which were correlated.
Collapse
Affiliation(s)
- Pei-Wen Fan
- Xinjiang Key Laboratory of Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, China
| | - Li Huang
- Department of Radiation Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, China
| | - Xue-Mei Chang
- Xinjiang Key Laboratory of Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, China
| | - Ya-Ning Feng
- Xinjiang Key Laboratory of Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, China
| | - Xuan Yao
- CAMS Oxford Center for Translation Immunology, Chinese Academy of Medical Science Oxford Institute, Nuffield Department of Medicine; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK
| | - Yan-Chun Peng
- CAMS Oxford Center for Translation Immunology, Chinese Academy of Medical Science Oxford Institute, Nuffield Department of Medicine; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK
| | - Tao Dong
- CAMS Oxford Center for Translation Immunology, Chinese Academy of Medical Science Oxford Institute, Nuffield Department of Medicine; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK
| | - Ruo-Zheng Wang
- Xinjiang Key Laboratory of Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University; Department of Radiation Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, China
| |
Collapse
|
15
|
Han ZD, Zhang W, Wang W, He J, Zhu FM. The novel HLA-A*02:625 allele was identified in a Chinese bone marrow donor. HLA 2018; 92:94-95. [PMID: 29790279 DOI: 10.1111/tan.13256] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2018] [Revised: 03/04/2018] [Accepted: 03/06/2018] [Indexed: 11/28/2022]
Abstract
HLA-A*02:625 differs from HLA-A*02:06:01:01 by a single nucleotide substitution at position 806 C>T.
Collapse
Affiliation(s)
- Z-D Han
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China
- Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - W Zhang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China
- Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - W Wang
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China
- Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - J He
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China
- Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - F-M Zhu
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China
- Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| |
Collapse
|
16
|
Tao SD, Dong LN, Han ZD, He J, Zhu FM. Identification of 2 novel HLA-B alleles, HLA-B*55:02:09 and HLA-B*55:80 in Chinese individuals. HLA 2017; 90:48-50. [PMID: 28337861 DOI: 10.1111/tan.13020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 02/27/2017] [Accepted: 03/02/2017] [Indexed: 11/29/2022]
Abstract
HLA-B*55:02:09 and HLA-B*55:80 differ from HLA-B*55:02:01 by 1 single nucleotide substitution, respectively.
Collapse
Affiliation(s)
- S-D Tao
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Blood Center of Zhejiang Provincial, Hangzhou, China
| | - L-N Dong
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Blood Center of Zhejiang Provincial, Hangzhou, China
| | - Z-D Han
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Blood Center of Zhejiang Provincial, Hangzhou, China
| | - J He
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Blood Center of Zhejiang Provincial, Hangzhou, China
| | - F-M Zhu
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Blood Center of Zhejiang Provincial, Hangzhou, China
| |
Collapse
|
17
|
Zhang W, Tao SD, Han ZD, Pan LL, Zhu FM. A novel HLA-C allele,HLA-C*08:128, was identified in a leukemia patient by polymerase chain reaction sequence-based typing. HLA 2017; 89:168-170. [DOI: 10.1111/tan.12971] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Revised: 01/14/2017] [Accepted: 01/16/2017] [Indexed: 11/30/2022]
Affiliation(s)
- W. Zhang
- HLA Typing Laboratory; Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research; Ministry of Health; Hangzhou China
- Key Laboratory of Blood Safety Research; Hangzhou China
| | - S.-D. Tao
- HLA Typing Laboratory; Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research; Ministry of Health; Hangzhou China
- Key Laboratory of Blood Safety Research; Hangzhou China
| | - Z.-D. Han
- HLA Typing Laboratory; Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research; Ministry of Health; Hangzhou China
- Key Laboratory of Blood Safety Research; Hangzhou China
| | - L.-L. Pan
- HLA Typing Laboratory; Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research; Ministry of Health; Hangzhou China
- Key Laboratory of Blood Safety Research; Hangzhou China
| | - F.-M. Zhu
- HLA Typing Laboratory; Blood Center of Zhejiang Province; Hangzhou China
- Key Laboratory of Blood Safety Research; Ministry of Health; Hangzhou China
- Key Laboratory of Blood Safety Research; Hangzhou China
| |
Collapse
|
18
|
Tao S, He Y, Dong L, He J, Chen N, Wang W, Han Z, Zhang W, He J, Zhu F. Associations of killer cell immunoglobulin-like receptors with acute myeloid leukemia in Chinese populations. Hum Immunol 2017; 78:269-273. [PMID: 28111167 DOI: 10.1016/j.humimm.2017.01.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 01/13/2017] [Accepted: 01/14/2017] [Indexed: 12/28/2022]
Abstract
Many studies have investigated the relationship between KIR, HLA and acute myeloid leukemia (AML), but the results were different in different laboratories, and the data in Chinese population were limited. In this study, the distribution of KIR gene, KIR genotypes, HLA-C groups, HLA-Bw4, and KIR-HLA interaction from 273 healthy participants and 253 AML patients (M0-M6) in southern Chinese Han were determined to investigate the relationships among KIR, HLA and AML. The results showed that the frequencies of 2DS4del in M5 patients were significantly higher than those of the controls (65.0% vs 46.5%, P=0.0104, OR=2.135, P<ɑ'). The frequency of KIR genotype BX13 in the healthy controls was significantly higher than that in AML patients (3.7% vs 0%, P=0.0019, OR=20.2, P<ɑ'). No other significant differences in the frequencies of KIR, HLA and KIR-HLA interaction were identified between AML patients and controls. Our study suggests that 2DS4del may conduct a susceptibility to AML, and genotype BX13 might conduct a protective effect on AML.
Collapse
Affiliation(s)
- Sudan Tao
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Yanmin He
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Lina Dong
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Junjun He
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Nanying Chen
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Wei Wang
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Zhedong Han
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Wei Zhang
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Ji He
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China
| | - Faming Zhu
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Provincial Key Laboratory of Blood Safety Research, Hangzhou, Zhejiang, People's Republic of China.
| |
Collapse
|
19
|
Zhu FM, Zhang W, Chen NY, Dong LN, He J. A novel allele, HLA-A*33:97 was identified in a Chinese bone marrow donor. HLA 2016; 88:305-306. [PMID: 27781406 DOI: 10.1111/tan.12918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 09/28/2016] [Accepted: 09/29/2016] [Indexed: 11/30/2022]
Abstract
HLA-A*33:97 has one base substitution at position 287 A>T in exon 2 compared to HLA-A*33:03:01.
Collapse
Affiliation(s)
- F-M Zhu
- HLA typing laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - W Zhang
- HLA typing laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - N-Y Chen
- HLA typing laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - L-N Dong
- HLA typing laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| | - J He
- HLA typing laboratory, Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China.,Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, China
| |
Collapse
|
20
|
Park H, Lee YJ, Song EY, Park MH. HLA-A, HLA-B and HLA-DRB1 allele and haplotype frequencies of 10 918 Koreans from bone marrow donor registry in Korea. Int J Immunogenet 2016; 43:287-96. [PMID: 27511726 DOI: 10.1111/iji.12288] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Accepted: 07/25/2016] [Indexed: 01/19/2023]
Abstract
The human leucocyte antigen (HLA) system is the most polymorphic genetic system in humans, and HLA matching is crucial in organ transplantation, especially in hematopoietic stem cell transplantation. We investigated HLA-A, HLA-B and HLA-DRB1 allele and haplotype frequencies at allelic level in 10 918 Koreans from bone marrow donor registry in Korea. Intermediate resolution HLA typing was performed using Luminex technology (Wakunaga, Japan), and additional allelic level typing was performed using PCR-single-strand conformation polymorphism method and/or sequence-based typing (Abbott Molecular, USA). Allele and haplotype frequencies were calculated by direct counting and maximum likelihood methods, respectively. A total of 39 HLA-A, 66 HLA-B and 47 HLA-DRB1 alleles were identified. High-frequency alleles found at a frequency of ≥5% were 6 HLA-A (A*02:01, *02:06, *11:01, *24:02, *31:01 and *33:03), 6 HLA-B (B*15:01, *35:01, *44:03, *51:01, 54:01 and *58:01) and 8 HLA-DRB1 (DRB1*01:01, *04:05, *04:06, *07:01, *08:03, *09:01, *13:02 and *15:01) alleles. At each locus, A*02, B*15 and DRB1*14 generic groups were most diverse at allelic level, consisting of 9, 12 and 11 different alleles, respectively. A total of 366, 197 and 21 different HLA-A-B-DRB1 haplotypes were estimated with frequencies of ≥0.05%, ≥0.1% and ≥0.5%, respectively. The five most common haplotypes with frequencies of ≥2.0% were A*33:03-B*44:03-DRB1*13:02 (4.97%), A*33:03-B*58:01-DRB1*13:02, A*33:03-B*44:03-DRB1*07:01, A*24:02-B*07:02-DRB1*01:01 and A*24:02-B*52:01-DRB1*15:02. Among 34 serologic HLA-A-B-DR haplotypes with frequencies of ≥0.5%, 17 haplotypes revealed allele-level diversity and majority of the allelic variation was arising from A2, A26, B61, B62, DR4 and DR14 specificities. Haplotype diversity obtained in this study is the most comprehensive data thus far reported in Koreans, and the information will be useful for unrelated stem cell transplantation as well as for disease association studies.
Collapse
Affiliation(s)
- H Park
- Department of Laboratory Medicine, Seegene Medical Foundation, Seoul, Korea
| | - Y-J Lee
- Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - E Y Song
- Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - M H Park
- Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.,Korea Organ Donation Agency Laboratory, Seoul, Korea
| |
Collapse
|